
|Videos|December 9, 2021
Recent Data Surrounding the Appropriate Candidates for Long-Acting Cabotegravir for HIV Prevention
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Pharmacy Times spoke with Dr. Elizabeth Sherman, PharmD, about her session at the ASHP Midyear 2021 conference, titled "Long Acting Antiretroviral Therapy for the Treatment and Prevention of HIV Infection”.
In this video, Dr. Sherman explains the recent data surrounding the right candidates for long-acting cabotegravir for HIV prevention.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
Pharmacist Outreach Doubles SGLT2 Inhibitor Uptake in CKD
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5





































































































